<SEC-DOCUMENT>0001818382-23-000014.txt : 20230324
<SEC-HEADER>0001818382-23-000014.hdr.sgml : 20230324
<ACCEPTANCE-DATETIME>20230324070432
ACCESSION NUMBER:		0001818382-23-000014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230324
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230324
DATE AS OF CHANGE:		20230324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		23757635

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20230324.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:fb2cd16b-75b6-4efe-8e1d-4fdd2dfa05f3,g:370ea457-17a6-4f04-a963-f91935e0c853,d:8f3ce33f4a3243ba89ce8167816835ed--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20230324</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityCentralIndexKey" id="f-26">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20230324.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8f3ce33f4a3243ba89ce8167816835ed_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 24, 2023</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityRegistrantName" id="f-3"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityRegistrantName" id="f-4">Humacyte, Inc.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityFileNumber" id="f-6">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityTaxIdentificationNumber" id="f-7">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityAddressAddressLine1" id="f-8">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityAddressCityOrTown" id="f-9">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityAddressStateOrProvince" id="f-10">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityAddressPostalZipCode" id="f-11">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:CityAreaCode" id="f-12">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:LocalPhoneNumber" id="f-13">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324" name="dei:TradingSymbol" id="f-19">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324" name="dei:Security12bTitle" id="f-21">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324" name="dei:TradingSymbol" id="f-22">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i8f3ce33f4a3243ba89ce8167816835ed_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2022. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i8f3ce33f4a3243ba89ce8167816835ed_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20230324xexx991.htm">Press release, dated March 24, 2023.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i8f3ce33f4a3243ba89ce8167816835ed_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 24, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20230324xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id8696d7924b34a32909e171604bddefa_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:50px;margin-bottom:5pt;vertical-align:text-bottom;width:210px"></div><div style="margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-- Enrollment Nearing Completion in Human Acellular Vessel&#8482; (HAV&#8482;) Phase 2&#47;3 Trial in Vascular Trauma and Phase 3 Trial in Arteriovenous (AV) Access in Hemodialysis Patients </font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">--</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Multiple publications and scientific meeting presentations highlighting clinical and preclinical HAV results </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:115%">&#8211;</font></div><div style="margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">-- </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conference call and live webcast at 8&#58;00 a.m. ET today </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">&#8211;</font></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DURHAM, N.C., March 24, 2023 &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate accomplishments.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;During 2022, we continued to make significant progress across all of our clinical programs and are poised to maintain this momentum throughout 2023,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;With enrollment approaching completion in our Phase 2&#47;3 trial of the HAV in its vascular trauma indication, we have moved substantially closer to our anticipated filing of a Biologics License Application (BLA) in this indication. The potential of the HAV in vascular trauma was highlighted in a compelling key opinion webinar we hosted in December, featuring Ukrainian surgeons Drs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oleksandr Sokolov, Vasyl Shaprynskyi, and Oleksandr Stanko.</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We extend our sincere thanks to our Ukrainian colleagues for sharing their experiences using the HAV to treat patients with wartime vascular trauma. In addition to our vascular trauma indication, we are excited to be nearing completion of enrollment in our Phase 3 trial of the HAV in arteriovenous access for hemodialysis patients, with topline results anticipated one year following completion of enrollment. Finally, we continue to be encouraged with the preclinical progress of our small diameter HAV in coronary artery bypass grafting (CABG), which we believe further supports the utility of our HAV as a vascular conduit across multiple indications.&#34;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2022 and Recent Corporate Highlights</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enrollment nearing completion in Phase 2&#47;3 V005 trial in vascular trauma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; A total of 63 patients have received the HAV in the Company&#8217;s Phase 2&#47;3 V005 trial in vascular trauma. In addition, 17 vascular trauma patients have been treated with the HAV under the humanitarian program in Ukraine. All patient results will be included in the BLA filing with the FDA. The primary efficacy assessment of the HAV in trauma will be based on a 30-day patency in 50 patients from the V005 trial who have suffered vascular trauma of an extremity. This primary efficacy analysis will not include patients with torso injuries and iatrogenic trauma enrolled in the V005 trial, though data from these patients will contribute to the safety database. Currently, 46 patients comprising the primary endpoint population have been treated with the HAV in the V005 trial, and the Company plans to enroll approximately six more patients to complete the study. Efforts to accelerate the enrollment of the remaining patients in V005 include the recent addition of clinical sites in Israel and ongoing efforts to expand the V005 trial to Ukrainian sites. The Company plans to file a BLA for accelerated approval with the U.S. Food and Drug Administration (FDA) for an indication in vascular trauma within approximately four months after the completion of the V005 trial. The Company plans to seek accelerated approval of the HAV for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein is not feasible.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enrollment nearing completion in Phase 3 V007 trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">in arteriovenous (AV) access</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Currently, 238 patients have been enrolled in the Company&#8217;s Phase 3 trial of the HAV for AV access in hemodialysis patients. The V007 trial is designed to assess the usability of the HAV for hemodialysis, in comparison to autogenous fistulas, in up to 240 patients with end stage renal disease. Top-line results are anticipated one year after completion of enrollment of the final patients in the trial, based on the one-year follow-up period built into the study.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Publications and Presentations</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Six-year results from the Company&#8217;s Phase 2 trial of the HAV in peripheral artery disease (PAD) were published in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Vascular Surgery &#8211; Vascular Science</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The article, entitled &#8220;6-Year Outcomes of a Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass,&#8221; reports overall secondary patency rate of 60% at 72 months, as estimated by Kaplan Meier analysis. This patency compares well with outcomes from saphenous vein revascularization. There was no evidence of graft rejection or infection, and no patients underwent amputation of the affected limb out to six years. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2022, the Company hosted a key opinion leader (KOL) webinar on its HAV in the treatment of wartime vascular trauma, featuring presentations from Ukrainian surgeons Oleksandr Sokolov, M.D., Ph.D., Vasyl Shaprynskyi, M.D., Ph.D., and Oleksandr Stanko, M.D, who discussed the use of the HAV to treat war-induced traumatic injuries, including case studies from the first nine patients treated under the humanitarian program. Our Ukrainian colleagues observed 30-day patency and zero cases of infection in all patients treated with the HAV. A replay of the event can be accessed on the Humacyte website </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">here</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Also in December 2022, Ukrainian surgeons presented patient outcomes from the use of the HAV to treat wartime vascular trauma at two vascular conferences. Drs. Sokolov, Shaprynskyi and Stanko presented at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine in Kyiv, Ukraine. In addition, Dr. Sokolov presented at the 11th Munich Vascular Conference (MAC) 2022.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In November 2022, Alan P. Kypson, M.D., FACS, thoracic surgeon at UNC Rex Hospital and lead investigator in Humacyte&#8217;s large animal pre-clinical development of vessels for coronary artery bypass grafting, provided a six-month patency update of the HAV in a baboon coronary artery bypass grafting (CABG) model in an oral presentation at the annual American Heart Association (AHA) Scientific Sessions meeting, held in Chicago, Illinois. Dr. Kypson highlighted that the HAV was observed to maintain structural integrity for up to six months and functioned as intended to conduct blood flow to the heart. In addition, the HAV showed evidence of robust cell repopulation with vascular cells over time, which suggests the potential for the HAV to become a living vascular tissue supplying blood to the heart muscle.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agencies.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter and Year Ended 2022 Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no revenue</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022 compared to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$177.0 thousand</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021, and revenue was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. Revenue in all periods related to grants supporting the development of the HAV.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021, and were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$63.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$61.3 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. The decrease for the quarter ended December&#160;31, 2022 compared to the prior-year quarter resulted primarily from a decrease in non-cash stock-based compensation expense. The increase during the year ended December&#160;31, 2022 compared to 2021 resulted primarily from increased personnel and materials expenses designed to support expanded research and development initiatives and the support of clinical studies.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.8 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021, and were </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.9 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$21.1 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. The 2022 increases resulted primarily from the transition to being a public company and preparation for the anticipated U.S. commercial launch of the HAV, including increased personnel costs, external services and insurance costs.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.1 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$64.2 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021, and was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$72.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$54.7 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. The reduction in other net income for the fourth quarter of 2022, and increase in other net income for the year December&#160;31, 2022, resulted primarily from non-cash gains related to the remeasurement of the contingent earnout liability associated with the August 2021 merger with Alpha Healthcare Acquisition Corp.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.7 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, compared to net income of </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.6 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2021, and net loss was </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, compared to net loss of </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.5 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2021. The increase in net loss for the current-year fourth quarter compared to 2021 resulted from a decrease in other net income described above. The decrease in net loss during the year ended December&#160;31, 2022 compared to 2021 resulted from the increase in other net income described above, partially offset by operating expense increases also described above. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash, cash equivalents and short-term investments of </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$151.9 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2022, compared to </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$225.5 million</font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2021. The </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$73.6 million net use of </font><font style="color:#0a0a0a;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash, cash equivalents and short-term investments for the year ended December&#160;31, 2022 resulted from spending related to net operating activities for the period, including clinical and earlier-stage research and development programs, and preparation for the Company&#8217;s anticipated commercial launch. The Company believes that its cash, cash equivalents and short-term investments are adequate to fund operations through the end of 2024, past the Company&#8217;s current expected timelines for potential approval of the HAV in its vascular trauma indication.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.134%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top">Date&#58;</td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Friday, March 24, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58; 1-201-389-0920<br>Conference ID#&#58; 13736105</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Humacyte</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues that have the potential to treat a wide range of diseases, injuries and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.Humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials&#59; the anticipated characteristics and performance of our HAVs&#59; our ability to successfully complete, preclinical and clinical trials for our HAVs&#59; the anticipated benefits of our HAVs relative to existing alternatives&#59; the benefits and risks related to our humanitarian efforts in the Ukraine&#59; the anticipated commercialization of our HAVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; our rights and obligations under our partnership with Fresenius Medical Care&#59; the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology&#59; the timing or likelihood of regulatory filings and approvals&#59; timing, scope, and rate of reimbursement for our HAVs&#59; the outcome of our ongoing discussions with the FDA concerning the design of our ongoing V005 Phase 2&#47;3 clinical trial, including determination of trial size, and the scope of any approved indication for our HAVs&#59; and our estimated available market opportunity. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, the impact of COVID-19 on Humacyte&#8217;s business, and other risks and uncertainties, including those included under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022, to be filed by Humacyte with the SEC and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Humacyte Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Joyce Allaire</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LifeSci Advisors LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-617-435-6602</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Humacyte Media Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rich Luchette</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Precision Strategies</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1-202-845-3924</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">rich&#64;precisionstrategies.com</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> </font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="id8696d7924b34a32909e171604bddefa_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>December 31,</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant revenue</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,341&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,554&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,883&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,130&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,790&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,804&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,143&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,471&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,790)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(21,627)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84,578)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(81,208)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,118&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,767&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,772&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (net)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,154)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,041)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,070&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,212&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,613&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,731&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (loss) income and comprehensive (loss) income</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,720)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42,585</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,965)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,477)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,162,219&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,003,506&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,051,366&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,970,398&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share, diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,162,219&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,743,854&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,051,366&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,970,398&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="id8696d7924b34a32909e171604bddefa_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,838&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,208&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,340&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,039&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,034&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,094&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,757&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,050&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, net of current portion</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,853&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,109&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,374</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">164,359</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,466&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,747&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,538)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(414,573)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,174&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,533</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20230324.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb2cd16b-75b6-4efe-8e1d-4fdd2dfa05f3,g:370ea457-17a6-4f04-a963-f91935e0c853-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20230324" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20230324">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230324_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230324_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20230324_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20230324_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb2cd16b-75b6-4efe-8e1d-4fdd2dfa05f3,g:370ea457-17a6-4f04-a963-f91935e0c853-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20230324.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended" id="i346b78441db94dd0a415f775f6f07ccd_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dce73aa8-9357-4906-ae2f-a30aebd58512" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_DocumentType_dce73aa8-9357-4906-ae2f-a30aebd58512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_55e70261-2546-42e1-8c21-7de57f8f20a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_DocumentPeriodEndDate_55e70261-2546-42e1-8c21-7de57f8f20a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_03d59d0e-eed0-4e0f-8ca2-f85466c4b16b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityRegistrantName_03d59d0e-eed0-4e0f-8ca2-f85466c4b16b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4ee29fe6-3f7d-4c86-8a00-21edff479501" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4ee29fe6-3f7d-4c86-8a00-21edff479501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_17c88deb-97d5-4fa4-9bf5-9ec46e671e35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityFileNumber_17c88deb-97d5-4fa4-9bf5-9ec46e671e35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd5ffc5a-644a-4e76-8388-9f40eeb2efa2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd5ffc5a-644a-4e76-8388-9f40eeb2efa2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e7dd821d-fad3-42ea-9467-7c8575083e1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressAddressLine1_e7dd821d-fad3-42ea-9467-7c8575083e1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f3da5db2-e758-4d22-8d8a-eb1b3b81b50e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressCityOrTown_f3da5db2-e758-4d22-8d8a-eb1b3b81b50e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b8c2a543-9da6-4ea8-adab-c060ebde9272" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressStateOrProvince_b8c2a543-9da6-4ea8-adab-c060ebde9272" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_af7cf42a-c4ab-4c99-901c-729ac1763978" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressPostalZipCode_af7cf42a-c4ab-4c99-901c-729ac1763978" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7b78e3e3-07be-4a45-aa3a-dfc0d7b88749" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_CityAreaCode_7b78e3e3-07be-4a45-aa3a-dfc0d7b88749" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7f0509fa-2387-4c09-b289-31edc9c7bb29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_LocalPhoneNumber_7f0509fa-2387-4c09-b289-31edc9c7bb29" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_313a680a-0b67-4d5c-a1af-664e058d36f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_WrittenCommunications_313a680a-0b67-4d5c-a1af-664e058d36f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6b22c233-bbdc-444b-8073-faf97dcd1e4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_SolicitingMaterial_6b22c233-bbdc-444b-8073-faf97dcd1e4f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a8d65ffb-72db-4c7e-b773-c48213a39d0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_PreCommencementTenderOffer_a8d65ffb-72db-4c7e-b773-c48213a39d0e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_956fe788-e032-4aee-b2fc-c126c7fd7124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_956fe788-e032-4aee-b2fc-c126c7fd7124" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1e05198e-8c9e-4e62-b9b0-27eaf3ef4ae9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_Security12bTitle_1e05198e-8c9e-4e62-b9b0-27eaf3ef4ae9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5b6aa131-bf6b-4679-bc94-b9adbf1d4928" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_TradingSymbol_5b6aa131-bf6b-4679-bc94-b9adbf1d4928" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e97ffe5-2539-4c41-b8da-6d77225ccee6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_SecurityExchangeName_5e97ffe5-2539-4c41-b8da-6d77225ccee6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8e092845-15a6-41c1-8522-9cbdcd12b900" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityEmergingGrowthCompany_8e092845-15a6-41c1-8522-9cbdcd12b900" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5bf4a9b9-9a85-4cfb-bcda-6ebc7ec6c47f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityExTransitionPeriod_5bf4a9b9-9a85-4cfb-bcda-6ebc7ec6c47f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5a03c39e-4e09-4eb3-9d38-b883d4bab520" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityCentralIndexKey_5a03c39e-4e09-4eb3-9d38-b883d4bab520" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_800b907d-1840-4d65-be01-10dd5d73ba3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_AmendmentFlag_800b907d-1840-4d65-be01-10dd5d73ba3a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:to="loc_us-gaap_ClassOfStockDomain_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:to="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7163a0f4-72b7-40c7-9705-387fdc217f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:to="loc_us-gaap_CommonStockMember_7163a0f4-72b7-40c7-9705-387fdc217f7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_76fa78a3-806d-4668-a9cc-ff95a456953e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:to="loc_us-gaap_WarrantMember_76fa78a3-806d-4668-a9cc-ff95a456953e" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20230324_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb2cd16b-75b6-4efe-8e1d-4fdd2dfa05f3,g:370ea457-17a6-4f04-a963-f91935e0c853-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_d6868810-d331-4c9b-9d64-6fbc91bc2609_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2ceae3fa-521e-4d54-b27e-8b937d7ccf31_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8fcc1966-e9d0-400b-8dec-7a6d251d7c1e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0b7ba779-9ec0-48df-b8e5-881c2b36d0b3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_fb346bc3-e620-471f-b73e-87d2b9ad11c2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5387d9a1-58b4-49e7-9940-c6a0552c5243_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ba68a9ac-f848-4e37-b5ce-9cd7e50da485_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_24251b39-4e21-408c-a263-0a7aeb27bea3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_189e337d-0dc2-4ce3-9911-f09ab9e5524d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0f24e250-ccf5-412d-bcd3-b0b3f8989bd6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f084d483-0df7-4627-b1fb-af0de0428d11_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_4fb2e742-bc4f-4684-bee1-8e51ecc9c144_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3e1ddc48-e831-4eaa-87fd-3cfab8743c30_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_a2a5eb63-8af3-4c22-97e6-bad2f290b185_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3f4cea84-25c7-4c27-bbeb-62302812d705_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1e60cac2-47c3-492a-96bd-6c57b21647c8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_417f5572-8911-4b57-9833-df838bb5abc0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_22555491-dfa2-42d5-bcc8-1d080d6496e2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c7d825e6-fa32-4749-b380-2f1fdf999773_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0219f90d-cd3a-40d1-9df3-fa69f5fd97fb_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4a8ea6fb-5142-4a66-b2ad-43a781e113de_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_1611c396-1075-4108-8c55-3007541a128e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_01446654-1875-4218-bf06-919a09f8255a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1057b93e-ac6c-4c60-8cc5-51455eed9d55_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e8565434-2267-4aca-ac14-22ff3aa30707_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_5ff48619-27c3-419f-a4df-5a63cfe2c77a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3abc7513-da7f-4f4b-9ff9-11fe10028e5d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_923b6e05-455f-44ec-9c05-32d18fe49e2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_98fbc836-da66-409b-9df2-e1fe5a9a2580_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20230324_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:fb2cd16b-75b6-4efe-8e1d-4fdd2dfa05f3,g:370ea457-17a6-4f04-a963-f91935e0c853-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20230324.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_734803c9-7e5b-4ed7-a8ac-f20ea8a588fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_734803c9-7e5b-4ed7-a8ac-f20ea8a588fe" xlink:to="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1fb219d2-0c5f-4bbd-aea3-ec29b521e6dd" xlink:to="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7163a0f4-72b7-40c7-9705-387fdc217f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:to="loc_us-gaap_CommonStockMember_7163a0f4-72b7-40c7-9705-387fdc217f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_76fa78a3-806d-4668-a9cc-ff95a456953e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca51c023-1d08-4569-923e-ee47496a975f" xlink:to="loc_us-gaap_WarrantMember_76fa78a3-806d-4668-a9cc-ff95a456953e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_1c88e21b-8a8a-4336-a9ea-1fdacd68c6c8" xlink:to="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_dce73aa8-9357-4906-ae2f-a30aebd58512" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_DocumentType_dce73aa8-9357-4906-ae2f-a30aebd58512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_55e70261-2546-42e1-8c21-7de57f8f20a6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_DocumentPeriodEndDate_55e70261-2546-42e1-8c21-7de57f8f20a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_03d59d0e-eed0-4e0f-8ca2-f85466c4b16b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityRegistrantName_03d59d0e-eed0-4e0f-8ca2-f85466c4b16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4ee29fe6-3f7d-4c86-8a00-21edff479501" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4ee29fe6-3f7d-4c86-8a00-21edff479501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_17c88deb-97d5-4fa4-9bf5-9ec46e671e35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityFileNumber_17c88deb-97d5-4fa4-9bf5-9ec46e671e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fd5ffc5a-644a-4e76-8388-9f40eeb2efa2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityTaxIdentificationNumber_fd5ffc5a-644a-4e76-8388-9f40eeb2efa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e7dd821d-fad3-42ea-9467-7c8575083e1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressAddressLine1_e7dd821d-fad3-42ea-9467-7c8575083e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f3da5db2-e758-4d22-8d8a-eb1b3b81b50e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressCityOrTown_f3da5db2-e758-4d22-8d8a-eb1b3b81b50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b8c2a543-9da6-4ea8-adab-c060ebde9272" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressStateOrProvince_b8c2a543-9da6-4ea8-adab-c060ebde9272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_af7cf42a-c4ab-4c99-901c-729ac1763978" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityAddressPostalZipCode_af7cf42a-c4ab-4c99-901c-729ac1763978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7b78e3e3-07be-4a45-aa3a-dfc0d7b88749" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_CityAreaCode_7b78e3e3-07be-4a45-aa3a-dfc0d7b88749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7f0509fa-2387-4c09-b289-31edc9c7bb29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_LocalPhoneNumber_7f0509fa-2387-4c09-b289-31edc9c7bb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_313a680a-0b67-4d5c-a1af-664e058d36f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_WrittenCommunications_313a680a-0b67-4d5c-a1af-664e058d36f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6b22c233-bbdc-444b-8073-faf97dcd1e4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_SolicitingMaterial_6b22c233-bbdc-444b-8073-faf97dcd1e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a8d65ffb-72db-4c7e-b773-c48213a39d0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_PreCommencementTenderOffer_a8d65ffb-72db-4c7e-b773-c48213a39d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_956fe788-e032-4aee-b2fc-c126c7fd7124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_956fe788-e032-4aee-b2fc-c126c7fd7124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1e05198e-8c9e-4e62-b9b0-27eaf3ef4ae9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_Security12bTitle_1e05198e-8c9e-4e62-b9b0-27eaf3ef4ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5b6aa131-bf6b-4679-bc94-b9adbf1d4928" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_TradingSymbol_5b6aa131-bf6b-4679-bc94-b9adbf1d4928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5e97ffe5-2539-4c41-b8da-6d77225ccee6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_SecurityExchangeName_5e97ffe5-2539-4c41-b8da-6d77225ccee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8e092845-15a6-41c1-8522-9cbdcd12b900" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityEmergingGrowthCompany_8e092845-15a6-41c1-8522-9cbdcd12b900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5bf4a9b9-9a85-4cfb-bcda-6ebc7ec6c47f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityExTransitionPeriod_5bf4a9b9-9a85-4cfb-bcda-6ebc7ec6c47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5a03c39e-4e09-4eb3-9d38-b883d4bab520" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_EntityCentralIndexKey_5a03c39e-4e09-4eb3-9d38-b883d4bab520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_800b907d-1840-4d65-be01-10dd5d73ba3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_3ef351c2-d012-4f55-8cb0-b067afddf468" xlink:to="loc_dei_AmendmentFlag_800b907d-1840-4d65-be01-10dd5d73ba3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
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MRELR"2*Q9G*LK#!7,QK65WIJ7<UI7E-:O59%!;DFNF)L\ ^ 2BG!/;2D4;C
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MH6G.!3UMTVF.ZG( "B*RO>25^/333\M/T"('J7#050TNO/#"\A-?\4K'[3
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M9&O@_JA1J$[0:UL,3)M <SJCORV$+@\B?%@58B1CE(N7N2K8Q4IOI:""AHG
M_.(2BL8#[F6FQQJ;VK3,G-"2HYEK\"<@$M32BHX@(A5@U&C=EWLL\^V/Z[_R
M28.M4[9)PWIOE 2WBP!SYLS3G_[PYW#$/_D=#P=_?NJIIT(X>BSWJ@'X07B&
M,XB)M'SVV6?+7\\%:# DIG< F(VT $\;!D8B0.CXU6#.,#0P4M#S<Z C(86X
MGBS.P""O,,"<O%V%A$8*PS"\G82=>+AC\KX*^C2W"@)>+AB-H9?TZ02L=,1?
MGP H#YV#E0HZ,HS)*@MAG)D=/%V6JZ EY?-[O[VN'J8J<#]HP>MOE,M5I^H
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MXYJ:7K^6QM2KK0DV:Y]SPS4V _]8N0MFFO0P'2W13F76.<I,NH3S#>4-\H\
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M&=\KGYR.N\7#.7@<1T]O1\#S<_2TD@$W_/U5=^S; YY>2!MZX6;HRW^^/ =
MU7@9P$I@C^'S9(;!'@M#K6D*D))Q7B(TC_$%=B"1?940SXL242['K42K!*2Q
M+;J47Z]J04,E"$[%2XIS5;)JN98]\*"F[MM&:YJGFJK0P"0MUZC6#Y];7V<Z
M+I?[9=ESMC'SZA9U-;%-:ZUYI4O8[2G--3+0RT/J_(5N$G+C+P!$"^2RRIG^
MM6C^;(T>.3)\$CC.0%X1)S)O]G(A!N'\B]]>8:Y4Y8(,+@(A'$R"GX.'XZU=
MWECF-?;D2S1X$YGG. .[/V8R$LY-TN:>"M+$[F5W()R;W,? J_CNYL!S/%S\
MV<O$Z_A+ERT-5YA^W;^?>GW6.Y@\+UZZ1+E<2&X 8R-5@5FS9FG$Z%'ARM.-
MFS8%V@1]EY8WCB18*#/,9J[+5ZW1L%&C#"U\[A9"::&E/7+L&(T:-U:C,0W'
M3A@?KE;EJM6Q-ID;.V9LN&*59\J3E9T=TMV2EQORYFI5KE,%N5J5JUAI,]#=
MN1TIF7;)8),XBFE(R2F\/2$?BS*6*/O#]S2Q:0MEI#35NB;UM-Y4A,P67*U:
M3QMAX!1CZ'"IGS%UB]I:W+26QI]Z$N^6FXY;HER6'@/ O)'J$/H?>9$MD[A@
MA84MA!6V>X^N.N744\/-B_%7XP%O0)ZY"9*KEK@"B1M['(C#G0GMVK4+%Y=P
MIX SL,=WDQMVN-Z)6Q*___[[2L3B57V_> [P<A W7IYD=TP8DOO3_'5\S\\A
M'H\[)WAUWB_PB'>8.,3C  L6+ @?N+W,:'#&66?JG//.#=>KGGWN.>&JU4LN
MNU1=NKZBN7Q4QL#C#OYQB$X\Y22=8/CIY[W,Q_)$=S/Z,RF)5@L,S<S-S=,]
M]]ZG$XU&UUYWK39NMLFWP8<??Z2V'=JI?><..JVCT?F,3FK+-:NG=S1[9W4P
MD_L<.G?J%-JA\^FG:_R$"2%N>D:ZVIH;]Z]QYP77JG9HWT$=K:VX4M6O5P5I
MWV3:)<,O[@>V*I@E3\OZ?:;5-]^@174:*+MN+6UL8NH".JXQ<(8QZ[KFM<.E
MUAFF4JS<VR9Q]KPXM;XF&_%DL\Y\&Y80P('>8:QA;=DD*AGA1J=GO=?L0:>R
MQP)3^E]][?7P)60N!7&IYHT'> ,CW;C? 4+Y%:K>2# P[A#$+[Z.@S_#M-Q3
M!I&YJP!P/^XJ./OLL\,%)X"7!< $XV6BDP#<)\'U4-QZB;2K"CP^R/T7E)/;
M-4FO.@8&N+^".-R9RZT_G:R.'6CLTSL%QH6!SSKG[' W<(=.'=6N8_O0D;@_
MP^/GF51^\)$'U;9C6YU[_CE*X[L6-@J[%&9UH9"S'-8H(X8-5]M33].I)YZD
MK_OVL8)'97OWW;=-.!@#P[S&N&T[F7FF,>TY9X1[@KD;N*/5R=L 6OC'YKG;
M&)ISQQSNV D#(\<9&.'#U;/4=VL0)G'.O$A%6 P&'O'( UIX]IF:W[21-C5K
M9"J#25EC5B1P9HN:AGN9]*VK]!8-M+R53>I:U->*O9MJ^'''T(K&F#9!8QT1
M#@V8:/P$AA]H9MD%+<: 8:ZK20VDZIEGGAD('MP3C!('&)@>RDV-7)X,. ,_
M]]QS0;*2CE__5!4,&C0H2%\NI7,&=N!B#=+@?C:D'6DXDWIY,'%W$RG*A=E<
M:\6=O%4QL)<%D]ML:"CN..8B$IC7TTX&9VRD.QV+2PG!&VZ\03_^_)-6IZU1
MUKILK4E/"W?NPKC4GSH0GA$+(%^&YQ-//$&GF#\=U>L 8(:1SX3)U5=>I5-.
M.ED=VK77BF7+Q75@\$GVVBRM6;6Z_!9[F+)OW[[ADL/3C.$9>;@XD4M>N!J+
M,"RCD0]NM!EE@U9T>%0Y5"E,_+$3!S^G5W50_CGU\&,/D03.U_B7GM&"BR[0
M/%,?UC8U]<$PJVE=D[KUC9%K11=<FP3.;-98*ULT5EK+^EK5LH'&[;NW\OOT
ME6SX89NYP(@1+K>V9&D#Z!0$<L@/"8SZ8&A,3F%?>.X9'7GX$3KMM-,J-:9+
M0*\0E8.YN#^,1@ @/.&X&8=+^[ALV1G8XV%ZNMP@PYV_W,P8OT4'0#+"V*3!
M-:-<>0JX.A*7E"X9N=&&1B0>4MU5B'@]XOES]YO?)TSX>(-ANMV!RP=I=,+#
M!*@Y7!$;2!E4P8KT82INN$&J41<8RM/+S,C4]==>I\,./<PZP6G&T..">[C@
M.C2.3/J.T#%'':VCCSQ*KW;KKB(.]^#/TIA!.!P5:&#EM,;]_H?OPYUJT LF
M="BO@QG8,ZQ<Y$L=N$TH^5:D\O &U,.%1G40&#@JAH'1-8I?K)RYTY3>[15-
M:[FWJ0>F Z?4-QVX?IC$99@47M_,U J^D9'26.G&Q.G-ZVAUN-RZB:9T[*1-
MXR:K++_0^+@P;.+D63GR3.>E/&'V#..R,&ZYYUK&8;G&"/'<$T^K3>M] B,X
MLP!QA@%H;!J'N[_0(0&O,%<2'730096N(8T3QNU<W\35K=S)VZ>/#9$QX(Y;
M&)M+KKGSB^&,/,F#JXY(PQ'@<P=(4AJ&3@$3^X6#SK" QT$B(D&11-P.SY6Q
M7,OD8:H"+ORF7OOLLT^XG3Y^FZ:GZPC M$Q2RR^HMC^GXS=??:/##SG<Z'>@
M;KKY5FW:G!-6%XB:EU<0KN BKTLOOB0P/% I#WLF11#H/^ ;[;U/:QUX\$%*
MSXRN^0KM;/^^I :L3<_4?ONVT7[6;MR1EGQME)<="&6./5<%00<F2 AF/U2/
M)+?D;U+IH@5:<-.MFK7O 5IIJ@03MI5[U];*5K64#4,W;JSLIBG&X(VTJD4M
MI37?4ZM2:VO2WJD:<?89RI\PQA+C WD<#C*TO,(H9/F 2%YVX$(',C_4L$<?
M?EPM6[0,S)/,M'& F9!:W)SN5_E389#[O6!*&MH9N"I@ L4]PMSS^_GGGR=<
M(^!^,:Y<A<%@2M*"P2!HLM1 _:"ST. P+G;B<,L[X P<&CX1IT>/'B%-;D9G
M,D8YD%Y^1W&\[L1AQ8$1AYO-T2VYRXPPGEXRD*>/#,X((&YAA<$DZ>6771[J
M2(<;.RZ2P@ Z-G7!S^\Y\SH \3S=G1&,.E"G^#UUR8 ?;<:M^,P5XL+ Z^S/
MVP/13AR0,!'8@8&I?$&>-'^>TI]Y6M-//D&3C%%G&Z,N;5;3U(=&-K%+478C
M&-M4""9WS6HHH\F>6M*L@4:U3-6<*R]1P= ?%;Y[3%J%)FL+"U2(9+4\8.QH
M,=WL846B3 \^]* :-FP0I)XS"A"O'+!\^?(@I;EJ]+;;;@MN$)-P,#3$Y)[;
M^*75R<"UJ5SHS#W 7+X'>/HP%GX0F5O4L7,;))=0 ]YP3$Z0TEQCBJ[)I=8T
M#L-IG(&=V; S[*/CTW&XF(^E0!J>T8"))<!(XO% &I[\N?B92:NG5QUX7G$3
MB-M9RB)?ZL9%@J3)MRZH VY,LGQUQ./$P=,&T(&A(W7?&@.C7G"!-S?",X<A
M?2\32!D 3[>J?.-@DSCG("(B$TG(; 5F-P;B0+<VK%'>3]]KV:VW:6F[4[3H
MH+TUVU2'!8T::EGCAEIITGA5BDGFIC64UJR.5J0VT+QF337%).F4DT_1TN>>
MU=I!WT2WN9->*6]KT$&LD(AEMGJ"#ERDN^^]777JU@J$W5KA4?216!#"&=@)
M@)X(,2%4_,M#@!,*@(&Y?I5K3WOV[!G<'+CE$3]F^TSB^'@+5[.BLM!8 -_+
M0%<G+YB1KRHYXQ/.&=CS]$9!8E-NPJ$G,\%A,L?S/??<4UX^9U*0"2'7IW)_
M<'S"Z6&W!G&F=7#U#%6)*UEA/%9"6#NGDU ^.A:PM<[B=6($X_)MZH#^71TP
M.2-MKL1E;K$MV%;]=K$@]H_<!8,F:J85RL;VHGQ69QEV3'KR^LF2I2H=/4:%
M _IIPUNO:]G]]VCNQ>=KZLG':/R!K36F=5.-,C5CXMZ--:Y9/8U/J:-Q+5+T
MD^FT8T\Z5>,NO%C3'G]*V8,&JVSQ,FGC%I/,,+#E:,@Z\*UWWJ'=]M@]2%;T
M-XB(Z7:_R1N=%2D-\;E6%("8$)O)@1,S3')B1,#NSQ#=+Y3VCZ9X@\"X7#S-
M:@)2B0NC6?(A//FR]GS>>><%IJ*C< TH<6%T& "&X#L;0#Q/TD)WYRY<EHY\
ME*$#T:BH'VS$$)ZZ@ #?LN#.7&Z%CZ]/Q]/>7G"&AHF9G+)L2;JWWGIK&!FX
MEY>/N[A^NCUYH)]SKR]U@$FK _S\'F/4+%:,6$6"GIB,+EQ(SIQB:]>J.L3>
MR*#A&-H3#&S_/KQ#0QOMK>($,0O("X1IRTT,35?9V.$J&]A/);T^5.9+SYK*
M\;!6W7^KEMQXJ99<<XGF772AIE]PD<9>=H5^OO8&#7OD"8U_[T--&C!(&U;;
MC!5B6@:\17O#+;?I+W_;-4@[&(5A%5V,28Z;2#<?3B$&2T8 1*9QF!S E$A0
MEJKB#1"W.]&YE=P9V/TNN^RRD 9,AKZ).Y*/6]%A/IB6]&D(UIT]'A,R.@\2
MV1D8\(Z!BD">?M&UN]-8U(\\N9<XZ*KFY_Y(1YB,BZN]L\#<F)YW''#;FA_@
M%VO#+'1,.CQUHN.Z[DO8JM)P<+_>O7N'2\-)9VL,S.25,- -]!&0=@1I=_Q9
M9:EJ#3\9*EUP'=FBIVBEP*P(@ J>C@+B!F%+^?9MA"6\^\4"./IN9J;*5JV0
MEO&Y?Y.T*Y:$=^.*ERU0P<JEREV\4)N6+-2&Y4M-HUAOTI>C>J7AC,1U)CU_
M_X<_:@^3PE0$A"&X+1WD&09R-XB-M "\P1G^84K"P,#QAHPW"!(8:<--YJ[;
M.K"1 K,X P,T.$M7GC=QT8]9#4": >B-,"B,[@SLPS7E0&IS>SN2EJ'6W0$8
MEQO2F4#1T/BY!$:OI%-0)C9P<'<FC]?)(9ZNFPX\$]_+Q4<B$1:4&T2=8>Z0
M'"\9XGDPAZ#LC!*H=]4!DV__I +,"QT01IAT8%1'YB[0$=5J6Q 8.-3=T7XP
M< _H=$D$BKL1$A?D=OC><4C,,#"X$=_T G9VQ(?"&2HY0VJAN56FR!B^C->%
M2B)]&.#]LQML]O_;W_\N]$2&%9!A!71[ERY=PE(9$@-)YE\#\D9%)X:8$(E)
M0W6-^?'''P>&X%K\3S^-/NGEC,"R&6GX=C3N("H $IYXK()X8SFCH7+ V(P.
MOHL'XQ,7R<002X?QM6O XR)E*3/^OBJ"'W$Q44\H*YT#IO,R.51E9Y($)/OY
M,_3"SM8]G1XISZ?# ,^[.O!TH"D,S&<#*/_6&)C)-YV$3LQ:/6HA'W1!+<3D
M+ 1N?#("NFT+RL\#EZ,!30Q)$X(W\8L^S'F&R,^!*&%)S(*$=D@$8$$\WRP%
M,+%-U+@T@Y-,>399S+')VI92WKZ ]8D<)<#2#CM+N_S7+D'19UB%."#$=.09
MW0U5 B9C-@O@#D'1H6AHB.0?: &<(-XP2&IG8-]N=6#)BN]CH/?"M("7!7V8
M#Y7P@4)W=T!RP A(%]\^A4D /F*(BH _DS\F4'0VENS0VUE[1;+CSW(<4C#.
M0$P2&6;YM@0J#LP $,9' .KFP'<YR /]VJ59O*S$\_1)CXX# ]*Q@7C>54$\
M/GE 1R1P?",C&: =G81VH[/S';JM0;P^54'TE2(47;@N4=Z(71./_, 8QIDV
MT-N?29/P@B#AS3/X)\*$M(R0[*T'B<R7Z4N4SWT#X2M%O#84#5TEQM E?,'>
MXA/=/T=[PW4W!D+PG;BM%9YO0Z ?PV00'W &9I(#$Z"3,5& D>(-1\> F9"&
M,#!#F.^">8/ P)0#!O:U9,I-.B"30]+QSN#Q8& 8#$9S!L8/)B8M\H-)4(5@
M9NP,J6Z'@6E@RL]FA<<'R)\U;OP(SPC @21T10?"\LPV.?Z$94+)B3OW=XC;
M$0)(4!C0&3A.LZJ ^)Y&G(&WM@I!I_,/V*">T;&H%_3!A*:8"!M&#^_\U8%)
M8 +0>Z,>'!@RCH$Y(TMB3<+L"08. 0S,/[H PQK8T@DA82:+6VCN^1:^H*Q0
MQ2:-P\%UL(BA!R*1LG4/XIM4OO;:JT+ED, N,9UIX@2G)[-9@=3PSUG!3(1#
M8D(<F)L&9+L6AD6",7%B^"9]I ",T*U;MT TP!N-R9@SL.O Y(^_#[O8DSL9
MLWB^?L3$Q%4(@&$1J4P#PX2N'H%, OEL+JH1Z[%\]PY&9YG0=]N\[J@.3'"H
M-V&@ 5*6"2E,RU#.Z("^#$-21Z2]#^N>3IR6@*LG,!>3.H PR>&2P=N%B27Q
MZ7Q;8V#:C7+[/ #:LY%#_3'9X(F;K,AL#1*OU=,(4<.5,ZYC',(SX8B#61'
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MR;+'K6 %$#::$%<4(H&>?O G4@))@+7]F%/T[!AS_V6&!E 6^OHDW*?[[!2
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M:&:"5SU$,CH[5^6/6_1;#5:B$?F6^P0LAU\X1(_$"GW&(C(KBTII&,)&SSZ
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M^27,GS\_?'3\P@LO# /1\.'#RP< @#+$A:D+G3CP[&&P5Q4'P8@=0.-E $)
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M60&,YLK^"NF0GO<[GD$T>]J(=L8?'L&$OW$'&7S^YW_^)_ L_,JFK;\ ]?=
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M"-/[U)UGEA?0B-FMYTT?ILRD18=U[2&."$R6/3A#RT804RG2<&'AZ8+)]7!
M '-:PZ?D"&*6-%B"< $<U]P=2=,A[AY'SS<.:*#DQP!%7M"+.J#1Q(^A =2'
MZ3RTI-,R(+%\P>9?_%B=US,Y;R^C/\<!NK,I1UF8N9 VPA#AQ'((@X$+)X^?
MG*X#[BS7H'6[,$:CHFY5M9LC_O ,N_',.-C4C6M>GF<<X\"SU]V?D\,PT/!"
M$/2#ET &=V90Y.E*A[>O0W(ZVPO$B],' <PI"):*X"_HS*#'#(U^LZ- V@Q.
M;&"S[H_RP0#.H,= !O+L;EMSQPXM0-H"DYD*+[+$9<&.0.53$%5 W#T>SNW)
M^$^!?U@F1*:QD['Z1&E F"XO-R^LJ8+LF")D_AZFH[.2CJ>)]D(^<6:L#JK*
ME_*P)NWKOKY[&T?<R8>\=[;LE(]\2,?+SG-RA_Q'057Y54<KGN,T!;>7IML#
MI!-X(586D#RI_\X --O>MO.\_A[>VQ:0+G6,UX_Z>AO_L\'I457?V-DZQ]O-
M,;E^6W.O+ASFW\O[L3?A?H5?X5?X%7Z%?R7\*H!_A5_A5_@5_DWPJP#^%7Z%
I7^%7^#?!KP+X5_@5?H5?X=\"TO\'GVM_Z3P1[XL     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139679636463984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 24,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>huma-20230324_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20230324.xsd" xlink:type="simple"/>
    <context id="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-26">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-2">2023-03-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-3">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-4">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-6">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-7">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-8">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-9">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-10">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-11">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-12">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-13">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324"
      id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324"
      id="f-19">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i96aeb683c1414a1eb8eb9a16e124535b_D20230324-20230324"
      id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324"
      id="f-21">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324"
      id="f-22">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i88c5bd91f98444c29fe77bf6efc168e9_D20230324-20230324"
      id="f-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ia801865a82854824adc4a94b4aaa4904_D20230324-20230324"
      id="f-25">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (\X>%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "/.'A6]=UR_^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9++
M:L,P$$5_I6AOCQ\A"^%XDY)5"H4&6KH3TB01M1Y(4^S\?64U<2CM!W2IF:LS
M9V ZZ;ET 9^#\QA(8WR8S& CEW[#SD2> T1Y1B-BF1(V-8\N&$'I&4[@A?P0
M)X2FJM9@D(02)& &%GXALKY3DLN @ERXXI5<\/XS#!FF)." !BU%J,L:6#]/
M])=IZ. .F&&$P<3O JJ%F*M_8G,'V#4Y1;VDQG$LQS;GT@XUO#WM7_*ZA;:1
MA)68?D7-Z>)QPVZ37]OMXV''^J9JVJ)JBV9UJ&M>K7BS?I]=?_C=A8U3^JC_
ML?%-L._@UUWT7U!+ P04    " "/.'A6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M (\X>%:4,/9)%04  '(6   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MQ9AO;^HV%,:_BL6NIDVBD#C\[0H2I>U:W=M>5GI7:=->F,00JTF<V4XIWW['
M 9)6-YS0ZDI[ TFP'W[V.7Z.X[.U5$\ZY-R0ESA*]*@1&I.>MMO:#WG,=$NF
M/(%?EE+%S,"M6K5UJC@+\DYQU*:.TVO'3"2-\5G^;*;&9S(SD4CX3!&=Q3%3
MFW,>R?6HX3;V#^[%*C3V07M\EK(5GW/S+9TIN&L7*H&(>:*%3(CBRU%CXIZ>
M>]1VR%O\*?A:O[HF=B@+*9_LS4TP:CB6B$?<-U:"P=<SG_(HLDK \>].M%'\
MI^WX^GJO?I4/'@:S8)I/9?0H A..&H,&"?B299&YE^MKOAM0U^KY,M+Y)UGO
MVCH-XF?:R'C7&0ABD6R_V<MN(H[I0'<=\HEH;_\HI[Q@AHW/E%P395N#FKW(
MAYKW!CB1V*C,C8)?!?0SXZE\YHK,( !G;0-Z]FG;W_4]W_:E!_K>,M4BM-,D
MU*'>V^YMP"A8:,%"<SWO@-YE8H39D)MDFVPV:']_@3;DQO!8_U,%N!7L5 O:
MC#[5*?/YJ $IJ[EZYHWQSS^Y/><W!-<K<#U,?7PA_0SRTY"'35HY>WCWP<EG
M!*)30'2.@YAQ)61 +I. 0")4\N!*133KPMDMT+JHX"Z<]WPEM%$,&.]87 F&
MZUQG,?,WAC<A,_P6 M8KP'K'@(&:5*E4>:8UR=S M!&IR%1FB5$;^ XJ:7'Q
MBTN$L%\0]H\AO!(1)W=9O."J"@37<!SWQ!MV/8KP# J>P3$\#^R%W 20;6(I
M_.T"/4R'*PZZ)VZ_Y_6[0P1O6. -C\&;! &L<MW<7Y#</+XFE5'$%6F7=LDE
MTY"S4IF03)F2T(:1:W#Y-=N0;@?A=IW2?9UWD4_M'>3@@UPGE8:,RUUD*F1Q
M$T-[51C<=Z$5ZV.FY+-(_.J"@6O>33&TLDZXJ*]_AS:3VK"(_"72@XNV1I'V
M^R[F>6Y9%%S<UO,(3F"#=!@%%QBZV))PR\+@XG[^1?HP)[-0)IB'U(AXKG<R
M['GHU)3UP,6-_%$)8W@"$Q/'6;)S$%U)A0LM6:0YAE16 A=WZSFL:E\8D:S(
M+:2W$BRJY,%5:GE*WW=QTYXI?N+#]'!87]N]!4\"V*!]72X/Q _7JR4K*X"+
M&_9W9#=:9T!6"XC+U@*6-< ]J@A<QERM;#Q_!P7KW#).6;*I1,,%C<HP,EJ:
M/#W*Y"]?R -L@[3("^=VOU:YI\75ZF:,E@Y/CW+X*413@57<0"!?R&=>.5<U
M4@[L-@;NP!M@NPWZZD4 M^,)9%B09]E5Q%:5/+A [225?DYK_!QR'L(U-])_
M:I*4*?+,HHR33T[+#IJDD/PZ9*K2ZG'M#[Z?T+($T,X/?Z%"Z\%'B<L207%G
M?Q &MKQR25SZR^)7,N=^!D6C.B-QI0_&[2UW64<H7@%@80?6=.:;>"$K2TB-
MP/6WVPE&4E80BCO^?LK ;OR0)2M^\*VK1NAN,K^8_($QE;6#XB9_SP/.8[:
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "/.'A6&445]3<!   G @  #P
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "/.'A699!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ CSAX5IE<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "/.'A6E##V214%  !R%@  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ CSAX5I^@&_"Q @
MX@P   T              ( !6 T  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "/.'A6EXJ[',     3 @  "P              @ $T$   7W)E;',O+G)E
M;'-02P$"% ,4    " "/.'A6&445]3<!   G @  #P              @ $=
M$0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ CSAX5B0>FZ*M    ^ $
M !H              ( !@1(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ CSAX5F60>9(9 0  SP,  !,              ( !9A,
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  L!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20230324.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="huma-20230324.htm">huma-20230324.htm</File>
    <File>huma-20230324.xsd</File>
    <File>huma-20230324_def.xml</File>
    <File>huma-20230324_lab.xml</File>
    <File>huma-20230324_pre.xml</File>
    <File>huma-20230324xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "huma-20230324.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 27
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "huma-20230324_def.xml"
     ]
    },
    "inline": {
     "local": [
      "huma-20230324.htm"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20230324_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20230324_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "huma-20230324.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 2,
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20230324",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20230324.htm",
      "contextRef": "ia801865a82854824adc4a94b4aaa4904_D20230324-20230324",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.humacyte.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "huma-20230324.htm",
      "contextRef": "ia801865a82854824adc4a94b4aaa4904_D20230324-20230324",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock, par value $0.0001 per share"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001818382-23-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-23-000014-xbrl.zip
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M2[^\>K&^W/YIGQQ^]>(_4$L#!!0    ( (\X>%:NL_QS/@T  %%X   5
M:'5M82TR,#(S,#,R-%]L86(N>&ULU5UK;]RX%?V>7\&Z^Z$%0ENDJ >#38K4
MFRV">I,@\2*+!L6 3UO(C&1(<FS_^U*:A^<AS9#2C%;]$L^#NCSWC [O)7FI
M_/R/Q]D4_%!YD63IZS-T[IT!E8I,)NG-Z[/?KW^%\=D_WKQX\?-?(/SCGY^O
MP"^9N)^IM 27N6*EDN A*6_!5ZF*[T#GV0Q\S?+OR0\&X9OZHLOL[BE/;FY+
M@#WL;W^;O](<"XE"#J. AY HK6"LD(1$2XFE9EZ@_9<WK_S(4XP$$401,\VT
M1R"CH0\U1=0/E"?BP*^-3I/T^ZOJ'\X*!8QS:5&_?7UV6Y9WKRXN'AX>SA]Y
M/CW/\IL+['G^Q;+UV:+YXT[[![]NC2BE%_6WJZ9%TM30F$47?_QV]47<JAF#
M25J4+!55!T7RJJ@_O,H$*VO.#^("K2VJ=W#9#%8?082AC\X?"WGVY@4 <SKR
M;*H^*PVJO[]_?M_:);VH6ERDZJ;Z93^I/,GDEY+EY17C:FK0U];*ISOU^JQ(
M9G=3M?SL-E>ZV>PTSS>L5BAIA1*%%<J_MG5VT0/^D?"6NUB/ *YV]\.Q,.[C
M],/1X%Z;\4&='O!:-[TASV^H=ZD<ZMY===4;^ND1'^NVR$HV'>"V>.YF#?*T
M^N#*O%IT4QG:,YC6_2R&[C6HZK%4J53ST7+#-$CDZS/S:B)5,GF7EDGY=&GB
M7LZF[\T%C_]63Q,9QF$<(P]*WT>0",HAE2&!H>:"(BYPZ-%)N;JI)RJ%OW]9
M]E]W<J"',P??RA:-YJK([G/Q'-UFTZ:09:)5%=_BBY3-5'''%A<8F%4B,$?^
M9@X2+%""&B8P.'^^>':I"Y'3T],S'1DSF=C ,JW2@2S?]CX3A[U_UE=A@->N
M%TJ<WV0_+LRUA@*,JQ>P>E'+JMWBQ<Z/]S9?XF2Y.,#SHL6%R$RN<U?"#<JK
MW-#2H3*S_-WGU)ENST"62Y6;_+7!A8;[[ZV4YL<O%G_,(*+0! O%E*\9##!2
MD,B 0(XCDXURZD<R$D+[R$W,#;V,5- +B"^7+T %%GQ,E:NPFXBU%7=/NH81
MN#M3'82^AXD>8F^R.K#@]SBV*_I]C=V%?YVS:D[[Y6G&L^DDUD(@&H904>E!
MXGD<QE():":7$@?(R!TI6[%O6!Z;P!?@P!R=O9PWZ3HLX<XDG%BVEOX[B;31
MUT["W+0TF!@;'5@78'.#KM'VUV2J/MS/N,HG'H\XBR(*J1)&=['4D,<J@":+
M%IC[H?2X[Q9DGXV/37J+B%$!!'.$KM%TC3C;(-J-CF%BIPT3':+EKLL]@N2:
ML8%CXZX;NR&QH8V[*+]DTT0DI='W;V9VG2=L.M'<)R$7/E0A-K*,D)%EY)O<
M-Y*84R:14:>M+'?-CTV8SPC!$J*],AO8.ZS-?IR<6)TN=#C)L]WK3@)M,#>8
M1-M=61?IGE9=8^?[5&3Y79;7>P5?2F/V,KLWD^&GRTRJ2> ;A5*&8!!S @E5
M$:24>%"$S L"+ ),',/IWO[&)N1%7-G _!+4J W-8($<5-!=0^]^WFVC\='8
M'"9 ]R*R0^2VHJ=',-]O?^#X;N7L;LBWNZSG0MBGK"C9]#_)77UW<Q;&C#(!
M=4QB2)0?01X(!:F0D0H\R4@<=%H)V^AFI(/):H%G#A88M)T&D$9F'9?".O,U
M\%J8+57=E\(:F>B_%K9I]L]9#&MTK74UK+FUF_SO"WC#V-WD*\MSEI:_J7J&
MB0D.$/>I$3Q&D'BQ@ R'/O18Q!3'$5?,*I=HM#XVL7]64JD9XV9"NL!I;F/%
MQ"UXN#48P,/\0Z >52Z2HFZH323,4@6*6Y:;L*C-O3Z;9:D)DYGX#E@)6+IL
MK\!=GHBZT4\(G0>>W>C1_,/L'S1ZTWWBL6*!"WR;(_MO_\%AK\<-8X)F!:_Q
M+BZ<#PQJ6A;+3YY'B&;;@PP,>]U:C@?[&W4;!BZGK"@^ZOHV_B6;L22=H)@J
MWX\D]*3 D CEFWD%0E![E'&JS-2"2)>Q8+>+L0T(-<)*KW,U?YNC;+];;9FT
M$V\_?DZL8%=JG(7<[OV1U-S0P:"2;G=P6]=[6KJG^)=5VI K5J>>GL8FL <>
M%$('D" L(1?2A]SCOHYI3+D,;9/Z=<.C$W*=F1IPCEG[!EF'\_2N%)Q:JW;>
M.R7B3:YV2KTW# V6;#?!7T^O&[_O.)].5'%=Y8H3[<5$DMADSU)'D(383*&1
MYI!I3RJ/X%@BMV*2I>6QR6T)#GRKX5D&S%W"+&?&76@88C)LPX#[['?;V^X3
MWI6E8>>XVP[L3&MW&G38SE+B/C<:1IA?)Z6YE8CF6$4$F_A&M-%>3"!7"L%8
M!4@)004BQ'HS:\OXV.17@ZIR,X3_QO\.EG =MK.VV;/8S.K!R8FUZ$J'VW96
MB]_=-K.VC0VWE=7BQL9&5EL;=WF^G:E45@>&?IVRFXFOD)2"Q%#%5<6T8@S&
MD9;0%YKQ."*^\#U;;6Y8'ILP5^! A<Y>CYMT'19C9Q).K$1+_YT$V.AK)_5M
M6AI,>HT.K.NNN4'WO6.=Y;-ZX^@J2=7[4LV*"<,L4#ST8<RT#XG &-)(A9 S
MB36F'D>NFSM-W8Q-CJL-SA54\*T""VJTKEEK,[.VFSM]^1IF<\>9JD[[O^U,
M]-KV;3 [^&YONVM-F[Q[6G=/B=\]BEOSTZH/YN>>^)H(Q4PRC ,15<(W4U*N
M. RQ[^$881EYUL)OZF!LDE]B!$N0H$+IGAEOD&B?'7>EYL3J=F2E4X+<Y'JO
M)'G#X.")<I,[3<ER8[NNL?NSNDF*LMKCJ>\[I$)/L&HO)A(F:E/,( VYA*$(
M(HY1:#Z.W:+V9@=C$^\B"#V#=!1O(XFV ;H[-<.$9EM6.D3D9M=[Q.(M@P-'
MX69W=N-O2SMW\2Z?CK$Z$OX+*]6$H$@'081A7&VB$AY$D,:^#Z6._9CS@'%A
M/>MM[&%L\ET])&2.$AB8H,)I+^!F(@\KN#<])Y:P,S-.(M[K?2<5-UL<3,9[
M'5K7\?Z&7:/P-7M\+XW51"?SI[4L3N-@' 0!H<@HF)F8C&4 N1 Q1-*+/1D2
M&BKK\Q)[>QJ;L!<1R* %FW [GG!J(]@V5!^!MF%BMCMC':+W 39ZA/$VRP/'
M\P,.[@;V0Q=TK)BJ"__J(HU%C9Z(9(P#%4+-_"I))Q1R/_8@UDA+32F-(J?B
MR9T>QC80K-<^O@1W+ <_V/1>@9^\<\_S$+A3^;Q0TK&":H?9_2/!4?@Z\0BP
M429Z_#+(5M>/53RU8W_8VJDV]W9*IUH;ND?_3[FJS"F#L$HJWA?%O<JOJP<%
MY1^UKLXQ8T0U]204TF>0>!)!*K5OY!]2'6A)(\UM$X!#G8U-^@8O%&N P1PQ
MF$,&-6;[/. @U8=3@6,2>.*QH!=W3AF!+2F=DH*#Q@?+"VS=7$\-K*_I>:JJ
MJBS[F%]G#^F$L%BQ4',8(&+R Q:&D&,F(?%9%".%D"^MGS?2TL?8AHGM0T)U
M:6)F;G6#M>-AJC5";2<(O6@:9FK@QE#W,U2['/0_0+5F\\\Y/;7K5.O1J8:F
MW=+_^A1F-7*L5VN_?4R*"0H1$CX-(?*BJLC:BV$L@@#ZGGE/$$,XMI+YP9[&
M)O;M,P(51L?#$^VLVDT!CL+5J:<"3C0Y3P4.4G"D*4%[/X-.#0ZZNSU%.'R!
M>\2OGN,\_72;I:M''"%"PC @$,75&(!1#+GV0D@191[5,0X"9AOJMXV/3?8U
M/E #=%X W"'N<$CO0\>)E>W A%,$;W.Y4^C>,398S&YS8SU8M[9Q%^77/"E+
ME599_GVZ6/DST=D+(DY]!9D(!20B]$QT%D&5DP>!4I+*P+H"IK&'L<ES 1)L
MHK27:#.-AW7:FYP3B]61%R?![O6]DVJ;+0XFW;T.K>MW?\,.QQ>S'RI_RZM]
M>5':',E;;S^BNZW&97*]!;(C55 V>MOM6-Z&I>'.Y34YL'$PK[%!]YJ,:W/I
M1,6!R<U\ C$.(TB88"8:H.JMUCYCOA=YD6LI1F5X;$/_JLZ@ N=>=E%S=5AR
M71DXL>+LG.]46;'N::^"BMK0X'44Z_";RB<VON^Z_/GN\3IG:9%4 6!>CS$)
MM"9QB"C$=?TBHAHR(C4,6.@+K;"((NM)45LG8Y/@8GGOW2-X1KHH^W%=_VQ@
MU'8!M!]/PZR .E'480&TG8,>*Z -1@=> FUW:W<-=$_;SC*?J?PF26_^E6</
MY:U)^^Y8^C3Q&1=1@'PH6:0AT81#JC6%"&F%/ _'*K!Z=,R!?L8J]@56, <+
M%FB=]=Y(K;7D^Q(VD.H=N>HB_'U,]-%^H]VAY;_/N8818&_SGEN=]<KJQ_Q3
MGOU(#/P)Q3X/E1= $@1F%"!*0"K,6Q]+%&M%J,*ZTW[G5D<C'0966WJK1Z@N
M 7?<^=SFUW8HZ,_:,&-!!\*Z;X2VL-%_-W3;\)^S)=KB7NN^:%O[WF53ZU4\
M--9<Q'YHTH(PA,2K_ZLTC:$R:4' *,-!;'T$HKV;L0T'.^4^1ZF1ZE4=]7]2
M%W7R@J@3E4*-H0C*K?S)I?!I_9>X,J_>O%A^DLS_#]HW+_X'4$L#!!0    (
M (\X>%8^3D'P- @  -A    5    :'5M82TR,#(S,#,R-%]P<F4N>&ULU9M;
M;]NX$L??^RE\LJ^',:\B6;1=Y*3M07#:;=!FT<6^&+P,':&V%$A*DWS[,U*2
MMKDT%2PM;+W$L4QIAG_^/)P9R2]^OURO9E^AJO.R>+G']NG>#(I0QKQ8OMS[
M\^0M,7N_OWKV[,6_"/GK/Q_?S5Z7X7P-13,[K, U$&<7>7,Z^QRA_C)+5;F>
M?2ZK+_E71\BK[J3#\NRJRI>GS8Q3+NY_6CU/GH?(,D^T\AF1D( 88)'(%"./
MR5&5Q+^7SX6FX*32A&F'PQ*5Q-E,D&29%0IH,$IT%UWEQ9?G[1_O:ICAY(JZ
M>_MR[[1ISI[/YQ<7%_N7OEKME]5RSBD5\]O1>S?#+Q^,OQ#=:&:MG7>??AM:
MYX\-Q,NR^5_OWWT*I[!V)"_JQA6A-5#GS^ONX+LRN*;3_)=^S7XZHGU';H>1
M]A!AG BV?UG'O5?/9K-K.:IR!1\AS=K7/S\>W3%Y>KYVX:J!_5"NY^V ^6&)
M.!R[9>MN=WIS=08O]^I\?;;Z=NRT@H37P9-)NZY4<-D:_>W[R?/O]L\JJ!&9
M;K[O\,#--5IKF_D"EPT4$:[G>&ME588[@U:MPF5U>^;*>5AU1Q<1\D5WY0-?
M-Y4+S4(+::@(EFA0'BF,FCCC DD<L3-.&9/N3QW=KM'O;D%J"/O+\NL<+XP+
MPWG[3ZL+[S1Y8.Y:F\W\?E,T>9-#?>+\"A8L& .<>6+02R*%R/!K 8ZP%%V(
MF0E9,(/\OF/NKM\_KNI!%69E%:'"$')KSU7AP0K?Q?=FQ/S,57@A$D[S5;P]
MNXTE8ZQ64XZAW?7*H+][,YQV@JJ"^.YZ87XZNVYJ#496Z$9NNNCG-5DZ=[;X
MA$I#&WD/5ZZN/Z1/31F^'%SF]8)A#&4V<D*#2D1Z'XD#)P@$;KWB#+(8GX @
MN=IW7M]8NB8!5DU]>^0[$K]T9GN(#%C<\I]0>@>0^='_U^7:Y<4B.,4"!FS"
M(C5$JLP2RP40 *FES9S5*HW,RD,OM@/)R,M;CJKU+M!2KM=ET4W@/:P]5 O-
M,N%HDD1SKXFD01.KJ2+"Z!0#9SII/S8L]YW8+BM#5_4^)(,DW@%&/KNJ<D5S
MZWR6G#;X!3$TPXP]RPP&V8#[<++*M<HH\536M D?=QSHQ0:?"!N;2[M%+KYM
MO%='12JK]6V*#T<88NN%@"10$4XBQ;I$)J6("9X23S/ML,!+,ALA/7W4]G;8
M&"<1&5'5+;-QVRTXP;&+&$ +YPS!BAUCG:4H!?!$G* .?%1&,3Z(AA^M;3D1
M'6'ERA%DW)'E/X8J+^.;(K[&U&NA%&C*,T:XDAF1'!BJP!G1$91.!JLXEXW"
MP1VS6PX(_PP0FPN[$YO&1UCF;4U?-'^X-2RHB,I&VNZ7D6)=3Q/Z[SA)!N>3
M!>E9]E2^V7>[N&NU%Q=B(EP,EG4GL#@J0EF=E54G2E>N'9;G15-='981%A*
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M6\K3 :1G[?1?_?;E[=4'T_A8OZZ;Q@<6.6/#;ID2%ZNU'4S1K;7@&O:8QKO
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MC"<<C9%:'IB6$#;<3*YS9@QF4P:_ ?4Z)'_F^?75KW\'E' W]@#TP"P&W/?
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M3X:O*\7JD(9]3ZBB&(@N>6&4_I.NV$&)HN%.SJ+8S5X1V%BT:\5@I\ #17V
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MRVL0W&R2P@FG)!@@C;$*-ZF[ Z5*#K&%,Z,&W\KM5]W=AM1O+P8/CTO-"".
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M_(U67%2'GZYW>WSTV.3(;J'9.OBUYYDNG8I= $R[D.GL4:7LR19,,4X*N,!
MM'JY4VE_./R]EVAD2##[L<&YDOM7^Z1(9NV$9,>RVDI ?E! [M$Z ^;<C"+
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M,C R,S S,C0N:'1M4$L! A0#%     @ CSAX5J"#Z_V3 @  ^P@  !$
M         ( !P!   &AU;6$M,C R,S S,C0N>'-D4$L! A0#%     @ CSAX
M5KO\T;^G"   ,CX  !4              ( !@A,  &AU;6$M,C R,S S,C1?
M9&5F+GAM;%!+ 0(4 Q0    ( (\X>%:NL_QS/@T  %%X   5
M  "  5P<  !H=6UA+3(P,C,P,S(T7VQA8BYX;6Q02P$"% ,4    " "/.'A6
M/DY!\#0(  #80   %0              @ '-*0  :'5M82TR,#(S,#,R-%]P
M<F4N>&UL4$L! A0#%     @ CSAX5HOHPU9$*   .Z0! !@
M ( !-#(  &AU;6$M,C R,S S,C1X97AX.3DQ+FAT;5!+!08     !@ & (T!
(  "N6@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
